Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | RAB9A | P51151 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | CES1 | P23141 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065026 | 0.87 | MAPT (0.44) | L3MBTL1NPC1RAB9ASMN1; SMN2TSHR | |
| Aniline SCHEMBL4256412 | 0.87 | CES2 (0.50) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL28775846 | 0.80 | CES2 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL22115811 | 0.80 | CES2 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL13310823 | 0.80 | CA12 (0.47) | SMN1; SMN2CA1CA2LMNAKDM4E | |
| SCHEMBL22619 | 0.80 | CES2 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL247590 | 0.80 | CES2 (0.59) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL7219677 | 0.78 | TSHR (0.60) | SMN1; SMN2CES2CES1ALOX15TSHR | |
| SCHEMBL160814 | 0.78 | CES2 (0.56) | L3MBTL1NPC1RAB9ASMN1; SMN2CES2 | |
| SCHEMBL2835051 | 0.78 | CA1 (0.60) | SMN1; SMN2TSHRALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1974543-A | Prepn process of 3-amino-4-cetyl chlorobenzoate | SUZHOU KAIYUAN MINSHENG CHEMIS (CN) | 2007-06-06 | — | — | CN | claimed |
| EP-2334682-B1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN INC (US) | 2017-10-04 | — | — | EP | disclosed |
| CN-103113349-B | 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors as well as preparation method and medical application thereof | UNIV CHINA PHARMA | 2014-11-12 | — | — | CN | disclosed |
| CN-103113349-A | 4-imidazolyl quinoline and quinazoline ketone aromatizing enzyme inhibitors as well as preparation method and medical application thereof | UNIV CHINA PHARMA | 2013-05-22 | — | — | CN | disclosed |
| US-8217043-B2 | Compounds and methods for their use | FIBROGEN, INC. (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
| EP-2334682-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | Fibrogen, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010022240-A1 | PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS | FIBROGEN, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | FIBROGEN, INC. | 2010-02-25 | — | — | US | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| CN-1243724-C | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2006-03-01 | — | — | CN | disclosed |
| CN-1330631-A | Amide derivatives which are useful as cell factor inhibitors | ASTRA ZENECA LTD (SE) | 2002-01-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100047367-A1 | COMPOUNDS AND METHODS FOR THEIR USE | HIF1AN, HIF1A, EGLN3 | L3MBTL1 2445/4885NPC1 2108/4885RAB9A 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.